Examkin

Question

Difficulty: MediumMenstrual Cycle Abnormalities and Contraception

A 28-year-old female presents for a well-woman visit to discuss family planning. She was diagnosed with polycystic ovary syndrome (PCOS) three years ago, characterized by oligomenorrhea—with menses occurring every 3 to 5 months—and hirsutism. Her medical history is also significant for frequent headaches, which she describes as severe, throbbing pain preceded by scintillating scotomas. These headaches occur roughly once every two months, and she takes sumatriptan for abortive relief. Her body mass index is 34 kg/m². Vital signs show a blood pressure of 118/76 mm Hg and a heart rate of 76/min. Physical examination demonstrates thick, dark hair growth on her chin and upper lip. A urine pregnancy test is negative. She is in a long-term monogamous relationship, does not wish to conceive, and requests a reliable contraceptive that will simultaneously reduce her risk of developing endometrial hyperplasia.

Which of the following is the most appropriate management for this patient?

  1. Insertion of a levonorgestrel-releasing intrauterine deviceAnswer
  2. B
    Initiation of a combined oral contraceptive pill
  3. C
    Insertion of a copper intrauterine device
  4. D
    Measurement of serum 17-hydroxyprogesterone
  5. E
    Initiation of clomiphene citrate therapy

Answer

Insertion of a levonorgestrel-releasing intrauterine device
The levonorgestrel-releasing intrauterine device is the optimal choice because it releases a steady, localized dose of progestin that effectively thins the endometrial lining, protecting the patient from endometrial hyperplasia caused by the chronic anovulation (unopposed estrogen) of polycystic ovary syndrome. Crucially, as a progestin-only method, it is safe to use in patients with a history of migraine with aura, completely avoiding the elevated ischemic stroke risk associated with systemic estrogen.

Step-by-Step Solution

1
Identify the patient's dual management goals based on her history.
The patient requires highly effective contraception and progestin therapy to protect her endometrium from hyperplasia caused by chronic anovulation in PCOS.
Patients with PCOS have unopposed estrogen stimulation of the endometrium, significantly increasing their risk for endometrial hyperplasia and carcinoma.
2
Evaluate the patient's medical comorbidities against the WHO Medical Eligibility Criteria (MEC) for contraceptive use.
The patient has a history of migraines with scintillating scotomas (migraine with aura), which categorizes any estrogen-containing contraceptive as MEC Category 4 (absolute contraindication).
Combined hormonal contraceptives increase the already elevated risk of ischemic stroke in patients who suffer from migraines with aura.
3
Select the optimal therapy that fulfills both goals without violating MEC safety guidelines.
A progestin-only method, specifically the levonorgestrel-releasing intrauterine device, is chosen.
It thins the endometrium effectively (preventing hyperplasia), provides top-tier contraception, and is safe (MEC Category 2) for use in women with migraine with aura.

Key Concept

Estrogen-containing contraceptives are absolutely contraindicated (WHO MEC Category 4) in patients with migraine with aura; therefore, progestin-only methods like the levonorgestrel IUD are the safest choice to provide both contraception and endometrial protection in patients with PCOS.
Rate this question

Topics

Menstrual Cycle Abnormalities and Contraception

More questions from this topic